Centers for tobacco-dependent in the Czech Republic in 2016
Authors:
Kamila Zvolská 1; Eva Králíková
Authors place of work:
Centrum pro závislé na tabáku, 3. interní klinika 1. LF UK a VFN v Praze
1; Ústav hygieny a epidemiologie 1. LF UK a VFN v Praze
2
Published in the journal:
Čas. Lék. čes. 2017; 156: 19-23
Category:
Original Article
Summary
This article sums up the evaluation of the intensive specialized treatment of tobacco dependence in the Czech Republic according to international guidelines and the ratified Framework Convention on Tobacco Control of the World Health Organization. 36 centers (100 %) were evaluated in 2016 and compared with the same survey from 2012.
Most of the centers (24 of 36) are based at pulmonary clinics, opening hours for the smokers are on average 7 hours/week (0.5–40.0, SD ± 9, median 4). Average number of new patients is 55/year per center (2–449, SD ± 77.26, median 32). Follow-up period is 12 months in 27 centers, 6–12 months in 2 centers, 6 months in 4 centers, and 3 months in 4 centers. The average number of visits per year is 5 (2–11, SD ± 2.03, median 4.5). The baseline visit takes on average 67 minutes (66.81 in the range of 25−180 minutes, SD ± 32.24, median 60), follow-up visits 24 minutes (23.86 minutes in the range of 12–45, SD ± 7.7, median 20). Nicotine replacement therapy is indicated in most centers (33), varenicline in all of them except of one, and bupropion in 16 centers. Lack of personal and time possibilities is considered the most frequent barriers of broader activity.
In the future, working conditions should be more supported in those centers so that this needed, effective and highly cost-effective treatment could be more available to smokers.
Keywords:
intensive treatment of tobacco dependence, nicotine replacement therapy, varenicline, bupropion, follow-up, personnel
Zdroje
1. WHO Framework Convention on Tobacco Control. World Health Organization, 2003, updated reprint 2004, 2005. Dostupné na: www.who.int/tobacco/framework/WHO_FCTC_english.pdf
2. Toolkit for delivering the 5A’s and 5R’s brief tobacco interventions in primary care. World Health Organization, 2014. Dostupné na: http://apps.who.int/iris/bitstream/10665/112835/1/9789241506953_eng.pdf
3. Sovinová H, Csémy L. Užívání tabáku v České republice 2015. Státní zdravotní ústav, Praha, 2016. Dostupné na: www.szu.cz/uploads/documents/czzp/zavislosti/Uzivani_tabaku_2015.pdf
4. Croghan IT, Offord KP, Evans RW et al. Cost-effectiveness of treating nicotine dependence. The Mayo Clinic experience. Mayo Clin Proc 1997; 72(10): 917–924.
5. Hurt RD, Ebbert JO, Hays JT, McFadden DD. Treating tobacco dependence in a medical setting. CA Cancer J Clin 2009; 59(5): 314–326.
6. Králíková E, Kmeťová A, Felbrová V a kol. Centra pro závislé na tabáku. Časopis lékařů českých 2014; 153: 248–252.
7. Nohler E, Öhrvik J, Tegelberg A et al. Long-term follow-up of a high- and a low-intensity smoking cessation intervention in a dental setting – a randomized trial. BMC Public Health 2013; 13: 592–601.
8. Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56–63.
9. Nides M, Oncken C, Gonzales D et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166: 1561–1568.
10. Gonzales D, Rennard SI, Nides M et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47–55.
11. Tonstad S, Tønnesen P, Hajek P et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64–71.
12. Aubin HJ, Bobak A, Britton JR et al. Varenicline versus transdermal nicotine patch for smoking cessation. results from a randomised openlabel trial. Thorax 2008; 63: 717–724.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Smoking during pregnancy – effects on mother and child, the treatment options for tobacco dependence
- Smoking and pharmacological interactions
- Possibility of uterus transplantation trial in Czech Republic – indications, research and clinical experience
- Smoking and immunity